AVITA Medical, Inc. updated revenue guidance for the year 2023. As a result of these dynamics, the Company is revising its expected full year 2023 commercial revenue from the previously disclosed range of $51 million to $53 million to a range of approximately $49.5 million to $50.5 million, with lower and upper bounds reflecting growth rates of approximately 45% and 48%, respectively, over the same period in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.52 USD | +2.65% | -1.39% | -37.90% |
Apr. 17 | Wilsons Downgrades Avita Medical to Market-Weight From Overweight; Price Target is AU$3.03 | MT |
Apr. 11 | BTIG Research Downgrades Avita Medical to Neutral From Buy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.90% | 220M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- RCEL Stock
- News AVITA Medical, Inc.
- AVITA Medical, Inc. Updates Revenue Guidance for the Year 2023